By Chung Joo-won
SEOUL, July 10 (Yonhap) -- South Korean bourse operator Korea Exchange said Friday that it will review a business normalization plan by bio tech firm SillaJen Inc. to decide whether to delist it.
The KRX has been reviewing the company's listing, after the company's chief executive and key management were indicted over charges of embezzlement and breach of trust.
SillaJen submitted its business normalization scheme to the bourse operator, and the KRX will have to decide whether to accept it by Aug. 4.
In the case of granting a grace period, the bourse operator is also to decide whether it will lift the company's trading suspension. Trading of SillaJen stocks has been suspended on the tech-laden KOSDAQ since May 4.
SillaJen has come under fire after some of its executives sold stocks ahead of its regulatory filing in August 2019 that its key product Pexa-Vec failed clinical tests.
Since its market debut on Dec. 6, 2016, SillaJen has rallied to 152,300 won on Nov. 21, 2017 from 9,050 won on Feb. 20, 2017.
SillaJen finished at 12,100 won on the day of suspension, lower than its IPO price of 15,000 won per share.
Seoul's last-ditch home supply plan still in doubt over its viability
Korean foodmakers ramp up overseas push amid COVID-19 pandemic
Bumpy road lies ahead for Samsung, even after heir avoids detention
One month into eased social distancing, S. Korea wrestles with cluster infections, cases with unknown routes
Virus outbreak sheds light on overlooked side of highly touted 'fast' delivery services